Literature DB >> 21153140

Follistatin has characteristics of a primary response gene in porcine granulosa cells.

C E Lindsell1, V Misra, B D Murphy.   

Abstract

To explore the regulation of follistatin gene expression, porcine granulosa cells were incubated with the translational inhibitor, cycloheximide (CHX), for periods from 6-24 h. This resulted in a 3 to 10-fold increase in follistatin mRNA accumulation compared to vehicle treated control cultures. At 20 h, CHX augmented the follicle stimulating hormone (FSH) induced stimulation of follistatin mRNA accumulation by a mean of more than sixfold. Over 6 h, CHX elevated follistatin mRNA abundance twofold, while epidermal growth factor (EGF) increased the message threefold. CHX in the presence of EGF produced an effect additive to the EGF response. Results in the longer term differed, as pretreatment of granulosa cells with CHX for 20 h suppressed the induction of follistatin gene expression by both EGF and phorbol 12-myristate-13-acetate. By blockade of transcription with Actinomyocin D, an estimate of the half-life of follistatin mRNA between 4 and 8 h was made. Half-life did not appear to be affected by the CHX suppression of protein translation. From the observations of the occurrence of follistatin gene expression independent of protein synthesis, superinduction in the presence of CHX and FSH, and the interactions between CHX and EGF, it is concluded that follistatin is a primary response gene in porcine granulosa cells.

Entities:  

Year:  1995        PMID: 21153140     DOI: 10.1007/BF02953027

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  32 in total

1.  Activin-binding protein from rat ovary is follistatin.

Authors:  T Nakamura; K Takio; Y Eto; H Shibai; K Titani; H Sugino
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

2.  Demonstration in living cells of an intragenic negative regulatory element within the rodent c-fos gene.

Authors:  N J Lamb; A Fernandez; N Tourkine; P Jeanteur; J M Blanchard
Journal:  Cell       Date:  1990-05-04       Impact factor: 41.582

3.  Structure and expression of TIS21, a primary response gene induced by growth factors and tumor promoters.

Authors:  B S Fletcher; R W Lim; B C Varnum; D A Kujubu; R A Koski; H R Herschman
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

Review 4.  Primary response genes induced by growth factors and tumor promoters.

Authors:  H R Herschman
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

Review 5.  Follistatin and activin: a potential intrinsic regulatory system within diverse tissues.

Authors:  L V DePaolo; T A Bicsak; G F Erickson; S Shimasaki; N Ling
Journal:  Proc Soc Exp Biol Med       Date:  1991-10

6.  Regulation of human chorionic gonadotropin secretion and messenger ribonucleic acid levels by follistatin in the NUCC-3 choriocarcinoma cell line.

Authors:  L Y Shi; Z W Zhang; W X Li
Journal:  Endocrinology       Date:  1994-06       Impact factor: 4.736

7.  Follistatin gene expression in the ovary and extragonadal tissues.

Authors:  S Shimasaki; M Koga; M L Buscaglia; D M Simmons; T A Bicsak; N Ling
Journal:  Mol Endocrinol       Date:  1989-04

8.  Follistatin, an antagonist of activin, is expressed in the Spemann organizer and displays direct neuralizing activity.

Authors:  A Hemmati-Brivanlou; O G Kelly; D A Melton
Journal:  Cell       Date:  1994-04-22       Impact factor: 41.582

9.  Regulation of follistatin messenger ribonucleic acid in porcine granulosa cells by epidermal growth factor and the protein kinase-C pathway.

Authors:  C E Lindsell; V Misra; B D Murphy
Journal:  Endocrinology       Date:  1993-04       Impact factor: 4.736

10.  Primary structure of the human follistatin precursor and its genomic organization.

Authors:  S Shimasaki; M Koga; F Esch; K Cooksey; M Mercado; A Koba; N Ueno; S Y Ying; N Ling; R Guillemin
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.